Article in Internal and emergency medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Giuseppe MulèUnit of Nephrology and Hypertension, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, European Society of Hypertension Excellence Centre, University of Palermo, Via Monte San Calogero, 29, 90146, Palermo, Italy. giusemme63@gmail.com.ORCID http://orcid.org/0000-0002-8705-4911
Alessandra SorceUnit of Nephrology and Hypertension, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, European Society of Hypertension Excellence Centre, University of Palermo, Via Monte San Calogero, 29, 90146, Palermo, Italy.
Emilio NardiDipartimento di Scienze della Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica d'Eccellenza "G. D'Alessandro" (PROMISE), Unit of Internal Medicine, University of Palermo, Palermo, Italy.
Giulio GeraciUnit of Nephrology and Hypertension, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, European Society of Hypertension Excellence Centre, University of Palermo, Via Monte San Calogero, 29, 90146, Palermo, Italy.
Santina CottoneUnit of Nephrology and Hypertension, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, European Society of Hypertension Excellence Centre, University of Palermo, Via Monte San Calogero, 29, 90146, Palermo, Italy.
European Society of Hypertension · ITUniversity of Palermo · IT
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
Heart FailureLifeAminobutyratesBiphenyl CompoundsDrug CombinationsFollow-Up StudiesHumansTetrazolesValsartanAminobutyratesBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartan
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The nephroprotective effect of sacubitril/valsartan in heart failure: insights from the real-life clinical setting. · full record | OpenQuestion